Page last updated: 2024-09-05

sb 203580 and adenosine-3',5'-cyclic phosphorothioate

sb 203580 has been researched along with adenosine-3',5'-cyclic phosphorothioate in 1 studies

Compound Research Comparison

Studies
(sb 203580)
Trials
(sb 203580)
Recent Studies (post-2010)
(sb 203580)
Studies
(adenosine-3',5'-cyclic phosphorothioate)
Trials
(adenosine-3',5'-cyclic phosphorothioate)
Recent Studies (post-2010) (adenosine-3',5'-cyclic phosphorothioate)
3,48941,137507047

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aso, H; Hasegawa, Y; Imaizumi, K; Ito, S; Kondo, M; Mori, A; Morioka, M; Suganuma, N1

Other Studies

1 other study(ies) available for sb 203580 and adenosine-3',5'-cyclic phosphorothioate

ArticleYear
Prostaglandin E2 enhances interleukin-8 production via EP4 receptor in human pulmonary microvascular endothelial cells.
    American journal of physiology. Lung cellular and molecular physiology, 2012, Jan-15, Volume: 302, Issue:2

    Topics: Acute Lung Injury; Anthracenes; Butadienes; Cells, Cultured; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclooxygenase 1; Cyclooxygenase 2; Dinoprostone; Endothelial Cells; Humans; Imidazoles; Interleukin-8; JNK Mitogen-Activated Protein Kinases; Lung; MAP Kinase Signaling System; Methyl Ethers; Microvessels; Naphthalenes; Neutrophils; Nitriles; p38 Mitogen-Activated Protein Kinases; Phenylbutyrates; Pyridines; Receptors, Prostaglandin E, EP4 Subtype; Respiratory Distress Syndrome; RNA, Messenger; Thionucleotides

2012